- Open Access
Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration
© Wu et al.; licensee BioMed Central Ltd. 2014
- Received: 12 June 2014
- Accepted: 2 October 2014
- Published: 9 October 2014
The goal of this study was to assess the association between endometrial thickness on the chorionic gonadotropin (hCG) day and in vitro fertilization and embryo transfer (IVF-ET) outcome in normal responders after GnRH antagonist administration.
A retrospective cohort study was performed in normal responders with GnRH antagonist administration from January 2011–December 2013. Patients were divided into four groups according to endometrial thickness, as follows: <7 mm (group 1), > = 7- < 8 mm (group 2), > = 8- < 14 mm (group 3), and > =14 mm (group 4).
A total of 2106 embryo transfer cycles were analyzed. The pregnancy rate (PR) was 44.87%.The clinical pregnancy rate, ongoing pregnancy rate and the implantation rate (17.28%, 13.79%, 10.17%, respectively) were significantly lower in group 1 compared to the other three groups (p < 0.05). The miscarriage rate was higher in patients with endometrial thickness less than 7 mm. The clinical pregnancy rate, ongoing pregnancy rate and implantation rate were highest in patients with endometrial thickness higher than 14 mm, but showed no difference in patients with those of endometrial thickness between 8-14 mm.
There is a correlation between endometrial thickness measured on hCG day and clinical outcome in normal responders with GnRH antagonist administration. The pregnancy rate was lower in patients with endometrial thickness less than 7 mm compared with patients with endometrial thickness more than 7 mm.
- Endometrial thickness
- GnRH antagonist
- Pregnancy rate
In-vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) are widely accepted as effective treatment for most causes of infertility. Gonadotropin-releasing hormone (GnRH) antagonist is now widely used in controlled ovarian stimulation cycles, which requires less follicle stimulation, and has lower risk for ovarian hyperstimulation syndrome (OHSS) [1, 2]. A randomized controlled trial (RCT) showed that normal responders treated with the GnRH antagonist protocol exhibited the same high success rates as patients treated with the long GnRH agonist protocol. The GnRH antagonist protocol is as effective and safe as the long GnRH agonist protocol .
Age, quality of the embryo and endometrial receptivity are the most important factors for the success of IVF. Endometrial thickness (EMT) has been accepted as an indicator for endometrial receptivity, and assessment of the endometrium in the midsagittal plane via transvaginal ultrasound is the standard procedure. Several studies have shown a significant correlation between pregnancy rate and endometrial thickness [4–7]. These studies reported a threshold of <7 mm with a significant reduction in the implantation rate and pregnancy rate. Recently the first systematic review and meta-analysis investigated both the independent predictive capacity and the prognosic value of endometrial thickness on pregnancy outcomesafter IVF. This study found that the probability of clinical pregnancy for an endometrial thickness ≤7 mm was significantly lower compared with cases with endometrial thickness >7 mm (23.3% versus 48.1%) and OR was 0.42 (95% CI 0.27–0.67) . There are few studies examining the association between endometrial thickness and clinical outcome in the GnRH antagonist protocol. The aim of this study was to assess the association between endometrial thickness on the HCG day and IVF outcome in normal responders after GnRH antagonist administration.
This study was reviewed and approved by the Institutional Review Board and Ethics Committee of Shanghai First People’s Hospital, China. This study is a retrospective cohort study and analyzed 2106 normal responders in International Peace MCH Hospital Shanghai Jiaotong University. All fresh embryo transferred patients after GnRH antagonist administration between Jan. 2011 and Dec. 2013 was included except poor responders according to the Bologna criteria  and patients with polycystic ovary syndrome (PCOS). Patients with abnormal uterine cavity per HSG or hysteroscopy were excluded from this study.
rFSH/HMG (rFSH-Gonal F-Merck Serono, Puregon-MSD, HMG Lizhu China) was initiated at a dosage of 150 U-225 U per day on day 2 of the cycle. The ovarian response was monitored by ultrasound and serum LH, E2 and P on day 6 (stimulation day 5). The need for additional doses of rFSH/HMG was determined based on follicular maturation, as assessed by ultrasound and E2 measurement. The GnRH antagonist (Cetrotide 0.25 mg-Merck Serono) 0.25 mg/day was added when at least 1 follicle reached 14 mm in diameter until hCG administration. When at least three follicles had reached a diameter of 18 mm, a dose of hCG (hCG, Lizhu China) 6000 U was given and oocyte retrieval was performed 36 hours later using vaginal ultrasound guided follicle aspiration. The endometrial thickness was measured in the midsagittal plane via transvaginal ultrasound on the day of hCG administration. A maximum of 3 embryos were transferred after 2 or 3 days in culture.
Luteal support was administered by intramuscular progesterone (dose 40 mg/day) beginning on the day of oocyte retrieval.
Clinical pregnancy was defined as the presence of at least a gestational sac on ultrasound 28 days after embryo transfer. Ongoing pregnancy was defined as the presence of at least one fetus with heart activity more than 12 gestational weeks. Implantation rate was calculated as the number of sacs with fetal heart beat over total embryos transferred.
All patients were divided into one of the following four groups according to their endometrial thickness: group 1 (n = 29): <7 mm; group 2 (n = 162): ≥7 mm to <8 mm; group 3 (n = 1852): ≥8 mm to <14 mm; group 4 (n = 64): ≥14 mm.
Statistical analysis was performed using the statistical package for Social Sciences (version 14, SPSS Inc, Chicago IL). The X2 test, t-test and ANOVA were used. P <0.05 was considered as statistically significant.
Demographic and pretreatment characteristics
N = 29
N = 162
N = 1852
N = 63
33.12 ± 3.46
32.34 ± 4.02
31.89 ± 3.67
31.98 ± 4.16
No. of Previous IVF attempts
Two or more
7.84 ± 2.44
8.13 ± 2.12
8.87 ± 5.28
Baseline E2 (pmol/L)
167.71 ± 90.66
184.48 ± 160.48
169.85 ± 253.51
132.88 ± 57.19
Outcome of ovarian stimulation
N = 29
N = 162
N = 1852
N = 63
Total dose of Gn
Duration of Gn
8.55 ± 1.45
8.52 ± 1.59
8.67 ± 1.49
8.86 ± 1.45
Duration of antagonist
3.68 ± 0.81
3.59 ± 1.21
3.67 ± 1.22
3.62 ± 1.24
Serum E2 on hCG day
9238 ± 1902.29
10457 ± 5391.63
10166.89 ± 6192.71
9962 ± 4662.25
Outcome of pre-embryonic development
N = 29
N = 162
N = 1852
N = 63
No. of oocyte retrieved
9.34 ± 6.0
10.78 ± 5.41
10.82 ± 5.60
11.02 ± 4.59
No. of oocyte fertilized
No. of embryo transferred
2.03 ± 0.57
2.01 ± 0.39
2.02 ± 0.37
2.07 ± 0.32
No. of embryo cryopreserved
2.72 ± 3.68
3.01 ± 2.96
2.97 ± 2.94
2.88 ± 2.89
N = 29
N = 162
N = 1852
N = 63
Clinical pregnant rate
Among 29 patients with thin endometrium (Group 1), 19 patients was secondary infertility before they were included in the study. However the number of the patients with previous IVF attempt in this Group was higher which may have affected the result; nevertheless the pregnancy rate in patients in first cycle was quite low (6.7%, 1/15). The pregnancy rate was 40% among patients in second cycle (4/10), and three of four patients among them who had an endometrial thickness more than 8 mm in previous long GnRH agonist protocol cycle got pregnant in this GnRH antagonist cycle.
Endometrial receptivity is one of the most important factors in predicting pregnancy after in-vitro fertilization and embryo transfer. Endometrial thickness has been utilized as an individual indicator for endometrial receptivity and is measured in the midsagittal plane via transvaginal ultrasound, which is considered as a non-traumatic and a simple method . The endometrial thickness measured on the day of hCG administration is most often used.
The effect of endometrial thickness on the success of IVF-ET had been evaluated by many studies [4–7, 10, 11]. Recent studies have reported a threshold of <7 mm with a significant reduction in the implantation rate and pregnancy rate [5–7]. Meta-analysis showed that the probability of clinical pregnancy in patients with endometrial thickness less than 7 mm was significantly lower compared to patients with endometrial thickness greater than 7 mm [23.3% versus 48.1%, OR 0.42 (95% CI 0.27–0.67)]. Positive and negative predictive values for the outcome of clinical pregnancy were 77% and 48%, respectively . Kumbak also found that the clinical pregnancy rate was 26%, miscarriage rate was 31% and live birth rate was 17% among patients with endometrial thickness less than 7 mm. However, these results were relatively good when the patient age was <35 years or the number of oocytes retrieved was over five or the number of available embryos to transfer was ≥3 . Thus, no conclusive cut-off value of endometrial thickness has been established.
The findings of endometrium thicker than 14 mm are controversial. Several authors suggested a detrimental effect of endometrial thickness of ≥14 mm on pregnancy rate , while the results of other studies have suggested that a thick endometrium increased the pregnancy rate . Quintero reported a woman who successfully conceived with an endometrial thickness of 20 mm .
Most studies examining the association between endometrial thickness and clinical outcome were performed using the GnRH agonist protocol. With the antagonist protocol being increasingly used, Al-Inany updated the Cochran review in 2011. Forty-five randomized trials (RCT) (n =7511) were included. The results showed that there was no evidence of a statistically significant difference in the rates of live births (OR 0.86, 95% CI 0.69 to 1.08), and there was a statistically significant lower incidence of OHSS in the GnRH antagonist group (OR 0.43, 95% CI 0.33 to 0.57) .
The GnRH antagonist was also recently introduced in China. A RCT comparing the antagonist protocol with the agonist long protocol was performed in normal responders. Antagonist treatment with a 43.7% clinical pregnancy rate was more efficient and safer than treatment with a long protocol and demonstrated equally high success rates . In our study, the clinical pregnancy rate was 44.87% in the normal responder with GnRH antagonist administration, which was consistent with the results described above.
There are few studies investigating the association between endometrial thickness and clinical outcome with GnRH antagonist administration. However, these results are controversial [15, 16]. Our study is a retrospective cohort study examining the relationship between endometrial thickness and clinical outcome using the GnRH antagonist protocol in normal responders. These patients were aged 20–39 and patients with PCOS and poor responder were excluded. Our study showed a positive correlation between endometrial thickness and clinical outcome, which is consistent with several studies [6, 16]. There were only five clinical pregnancies (17.24%) in our study, which had an endometrial line of less than 7 mm, of which one was lost. The number of previous IVF attempts was higher in these patients which might affect the pregnancy. Although the pregnancy rate was 6.7% in the patients in first cycle, the high previous IVF attempt is still a limitation of the study. The pregnancy rate among these patients is similar to the pregnancy rate (23.3%) in recently meta-analysis although most women in the meta-analysis were conducted in long GnRH agonist protocol .
Patients with an endometrial thickness between 7–8 mm had a decreased pregnancy rate, but no significant difference was shown when compared to patients with endometrial thickness in 8-14 mm.
Implantation is necessary for a successful pregnancy and requires healthy endometrial receptivity . The implantation rate (10.17%) was significantly lower in patients with thin endometrial thickness. Thicker endometria corresponded with higher implantation rates. These findings were consistent with a clinical pregnancy rate and ongoing pregnancy rate results.
In patients with thicker endometria (≥14 mm), the clinical pregnancy rate, ongoing pregnancy rate and implantation rate increased, but with no difference with patients with endometrial thickness in 8-14 mm in our study. This finding was consistent with several recent studies demonstrating no reduction in pregnancy rate with a very thick endometrium [6, 12].
Our study has some limitations, the most important of which is its retrospective nature. However, we believe that the results are of interest because similar studies had been published with conflicting results.
The results of the present study identified a correlation between endometrial thickness measured on hCG day and clinical outcome in normal responders with GnRH antagonist administration.
The authors thank everyone in the Department of Reproductive Medicine in the International Peace MCH Hospital for their scientific advice and encouragement. We thank the English professional service (http://webshop.elsevier.com/languageediting/) for their language editing.
- Copperman AB, Benadiva C: Optimal usage of the GnRH antagonists: a review of the literature. Reprod Biol Endocrinol. 2013, 11: 20-32. 10.1186/1477-7827-11-20.PubMed CentralView ArticlePubMedGoogle Scholar
- Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P: GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006, 12: 333-340. 10.1093/humupd/dml001.View ArticlePubMedGoogle Scholar
- Qiao J, Lu G, Zhang HW, Chen H, Ma C, Olofsson JI, Witjes H, Heijnen E, Mannaerts B: A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates. Gynecol Endocrinol. 2012, 28: 800-804. 10.3109/09513590.2012.665103.View ArticlePubMedGoogle Scholar
- Al-Ghamdi A, Coskun S, Al-Hassan S, Al-Rejjal R, Awartani K: The correlation between endometrial thickness and outcome of in vitro fertilization and embryo transfer (IVF-ET) outcome. Reprod Biol Endocrinol. 2008, 6: 37-41. 10.1186/1477-7827-6-37.PubMed CentralView ArticlePubMedGoogle Scholar
- Kasius A, Smit JG, Torrance HL, Eijkemans MJ, Mol BW, Opmeer BC, Broekmans FJ: Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update. 2014, 20: 530-534. 10.1093/humupd/dmu011.View ArticlePubMedGoogle Scholar
- Aydin T, Kara M, Turktekin N: Relationship between endometrial thickness and in vitro Fertilization/intracytoplasmicsperm injection outcome. Int J Fertil Steril. 2013, 7: 29-34.PubMed CentralPubMedGoogle Scholar
- Kumbak B, Erden HF, Tosun S, Akbas H, Ulug U, Bahçeci M: Outcome of assisted reproduction treatment in patients with endometrial thickness less than 7 mm. Reprod Biomed Online. 2009, 18: 79-84. 10.1016/S1472-6483(10)60428-2.View ArticlePubMedGoogle Scholar
- Ferraretti AP1, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L: ESHRE working group on Poor Ovarian Response Definition:ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011, 26: 1616-1624. 10.1093/humrep/der092.View ArticlePubMedGoogle Scholar
- Friedler S, Schenker JG, Herman A, Lewin A: The role of ultrasonography in the evaluation of endometrial receptivity following assisted reproductive treatments: a critical review. Hum Reprod Update. 1996, 2: 323-335. 10.1093/humupd/2.4.323.View ArticlePubMedGoogle Scholar
- Detti L, Ambler DR, Yelian FD, Kruger ML, Diamond MP, Puscheck EE: Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes. J Assist Reprod Genet. 2008, 25: 177-181. 10.1007/s10815-008-9217-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Bassil S: Changes in endometrial thickness, width, length and pattern in predicting pregnancy outcome during ovarian stimulation in in vitro fertilization. Ultrasound Obstet Gynecol. 2001, 18: 258-263. 10.1046/j.1469-0705.2001.00502.x.View ArticlePubMedGoogle Scholar
- Yoeli R, Ashkenazi J, Orvieto R, Shelef M, Kaplan B, Bar-Hava I: Significance of increased endometrial thickness in assisted reproduction technology treatments. J Assist Reprod Genet. 2004, 21: 285-289.PubMed CentralView ArticlePubMedGoogle Scholar
- Quintero RB1, Sharara FI, Milki AA: Successful pregnancies in the setting of exaggerated endometrial thickness. Fertil Steril. 2004, 82: 215-217. 10.1016/j.fertnstert.2004.02.099.View ArticlePubMedGoogle Scholar
- Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM: Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011, 11: CD001750Google Scholar
- Detti L, Yelian FD, Kruger ML, Diamond MP, Puscheck EE: Endometrial thickness dynamics and morphologic characteristics during pituitary downregulation with antagonists in assisted reproductive technology cycles. J Ultrasound Med. 2008, 27: 1591-1596.PubMedGoogle Scholar
- Giannaris D, Zourla A, Chrelias C, Loghis C, Kassanos D: Ultrasound assessment of endometrial thickness: correlation with ovarian stimulation and pregnancy rates in IVF cycles. Clin Exp Obstet Gynecol. 2008, 35: 190-193.PubMedGoogle Scholar
- Dekel N, Gnainsky Y, Granot I, Mor G: Inflammation and implantation. Am J Reprod Immunol. 2010, 63: 17-21.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.